Mar. 12, 2022
AZD7648
oral DNA-PK inhibitor Ph. I/II candidate for advanced tumors from screening for selectivity vs. PI3Ka Mol. Cancer Ther. AstraZeneca
oral DNA-PK inhibitor Ph. I/II candidate for advanced tumors from screening for selectivity vs. PI3Ka Mol. Cancer Ther. AstraZeneca